Status:
COMPLETED
Can Cytokines be Used as an Activation Marker
Lead Sponsor:
Maltepe University
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
RA is a chronic, autoimmune, inflammatory disease that involves small joints in the form of symmetrical polyarthritis and progresses with exacerbations and remissions. Pain, swelling, tenderness and m...
Detailed Description
Aims: The etiopathogenesis of Rheumatoid Arthritis (RA) is not clearly understood. However, role of the cytokines takes an important part of this mechanism. The investigators aimed to bring a new appr...
Eligibility Criteria
Inclusion
- Healthy individuals and Rheumatoid Arthritis patients meeting American College of Rheumatology (ACR) RA remission criteria.
Exclusion
- Smoking, Using Disease-Modifying Anti-Rheumatic Drugs (DMARD) and/or anti-inflammatory drugs other than cortisol and methotrexate, Receiving chemotherapy, Being hypothyroid
- \-
Key Trial Info
Start Date :
April 5 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 15 2018
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04486027
Start Date
April 5 2017
End Date
December 15 2018
Last Update
July 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Selim Nalbant
Istanbul, Turkey (Türkiye)